Answers are grounded in this paper and cite their sources.
Several molecular biomarkers have been identified for the tailored treatment of mCRC patients and multiple efforts are currently ongoing to increase the therapeutic options. In the era of precision medicine, molecular-biology-driven treatment is the key to impro patient selection and patient outcomes. Further research and large phase III trials are required to ameliorate the therapeutic management of these patients.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: